% | $
Quotes you view appear here for quick access.

Isis Pharmaceuticals, Inc. Message Board

  • wanna_million wanna_million Oct 31, 2012 12:03 PM Flag

    Zacks PT $11

    Risk Level * Above Average
    Type of Stock Mid-Growth
    Industry Med-Biomed/Gene
    Zacks Industry Rank * 70 out of 267
    Current Recommendation OUTPERFORM
    Prior Recommendation Neutral
    Date of Last Change 10/30/2012
    Current Price (10/29/12) $8.90
    Target Price $11.00
    Isis Pharma received a major boost in October 2012
    when the Food and Drug Administration s (FDA)
    Endocrinologic and Metabolic Drugs Advisory
    Committee voted (9 - 6) in favor of approving the
    company s lead pipeline candidate, Kynamro
    (mipomersen). Meanwhile, Kynamro could be
    approved and launched in the EU by year end. We
    believe that antisense technology (the main area of
    focus at Isis) represents an exciting and potentially
    revolutionary platform for developing therapeutic
    candidates to treat a wide margin of diseases. We are
    also positive on Isis agreements with Glaxo and
    Biogen, which not only validate its antisense
    technology but also provide Isis with funds in the form
    of upfront, milestone and other payments. With the
    favorable FDA panel vote, we are upgrading Isis to
    Outperform. A final response from the FDA should be
    out in January 2013.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
57.560.00(0.00%)Dec 21 4:00 PMEST